Format

Send to

Choose Destination
Br J Cancer. 2010 Apr 13;102(8):1219-23. doi: 10.1038/sj.bjc.6605635. Epub 2010 Apr 6.

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.

Author information

1
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

Abstract

BACKGROUND:

Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation.

METHODS:

A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17.

RESULTS:

KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain.

CONCLUSION:

The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status.

PMID:
20372153
PMCID:
PMC2856012
DOI:
10.1038/sj.bjc.6605635
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center